It’s no secret that we’re making nice strides in decreasing the mortality of lung most cancers. From bettering screening charges which have decreased the possibilities of dying from lung most cancers as a consequence of earlier detection, elevated adoption of minimally invasive surgical strategies, and thrilling new medicine which have been proven to enhance survival even in metastatic illness, there may be purpose to be hopeful in what has normally been a devastating and deadly prognosis. These newer medicine, reminiscent of immunotherapies and kinase inhibitors, usually require superior molecular testing to assist discover the best medicine for a affected person’s distinctive most cancers, like discovering the best key for a lock. Regardless of their confirmed efficacy, nevertheless, getting Medicare and different payors to pay for this molecular testing has confirmed to be an opaque course of not well-understood by physicians. To mangle a quote from Alexandre Dumas, Medicare fraud, like treason, is a matter of dates.
The 14-day rule is designed to stop laboratories from billing Medicare for exams carried out on specimens if a doctor ordered the take a look at inside 14 days of the affected person’s inpatient discharge. On the time of its enactment, one might see the logic, because it was designed to cut back prices by bundling inpatient-related costs to inpatient-related funds. Occasions change, nevertheless, and with the widespread adoption of molecular testing, we at the moment are in a spot the place we gather specimens as an inpatient that may then have to be analyzed to direct long-term outpatient remedy, and as with all issues, the query turns into, “Who can pay for it?” To make use of my very own medical expertise for example, if I resect a lung most cancers which may meet the factors for added remedy with considered one of these newer medicine, I’ve to attend 14 days till after the date of discharge (not the date of surgical procedure) earlier than I can ship molecular testing to assist information the affected person’s extra systemic remedy. If I order it earlier than these 14 days have handed, and the laboratory makes an attempt to invoice Medicare for performing that take a look at, that laboratory has dedicated Medicare fraud. That is an illogical and archaic rule, nevertheless it has not stopped the Division of Justice from aggressively pursuing laboratories that violate this regulation.
To Medicare’s credit score, the rule was even worse up till 2018, once they made an replace. Beforehand, the 14-day rule utilized to each inpatient and outpatient testing, which means that beforehand, if somebody had an outpatient biopsy and was discharged the identical day, the individual ordering the molecular testing nonetheless needed to wait 14 days earlier than they might order it. That rule was modified in 2018 in order that it not utilized to outpatient procedures assembly particular standards however solely to inpatient. For sufferers who want extra remedy, nevertheless, this pointless 14-day wait incessantly results in extra delays as it’s normally as much as the medical oncologists to order of their follow-up visits, incessantly delaying ordering, supply of outcomes, and finally remedy. In a survey printed in 2022 of ASCO members concerning their very own causes for not ordering molecular testing for superior lung most cancers sufferers, greater than half cited their very own considerations about delaying remedy as a purpose for not ordering molecular testing. My present establishment has developed legally compliant pathways that meet these necessities whereas minimizing delays for acceptable sufferers, however solely by way of important work.
Though my expertise is primarily within the lung most cancers area, molecular testing has a task in most forms of most cancers by this level, however illogical guidelines hidden behind layers of purple tape maintain most physicians from understanding the particular obstacles that their sufferers face to remedy. Medicare must create an exception to the 14-day rule for molecular testing for most cancers to reduce doctor administrative burden and assist sufferers get the remedy they want quicker. The period of personalised medication is lastly upon us, now we simply have to Medicare to catch up.
Sean Jordan is a thoracic surgeon.
